Who is sponsoring NCT00780403?

NCT00780403 is sponsored by Organon and Co.

What drugs are being tested in NCT00780403?

Interventions: Desloratadine, Zyrtec® (cetirizine).

What is the status of NCT00780403?

NCT00780403 is currently COMPLETED.

Last reviewed 2022-02-07 · How we verify

A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications

NCT00780403 Phase 4 COMPLETED Results posted

The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets

Details

Lead sponsor	Organon and Co
Phase	Phase 4
Status	COMPLETED
Enrolment	220
Start date	2005-08
Completion	2005-10

Conditions

Allergies

Interventions

Desloratadine
Zyrtec® (cetirizine)

Primary outcomes

Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet. — Following the second dose (8-10 minutes after the first dose)
A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.